RefleXion to Share Ground Breaking SCINTIX Therapy Research in 29 Scientific Presentations at AAPM 2025
July 25, 2025
Studies highlight multi‑tumor treatment accuracy, one‑year clinical experience and expanded radiotracer indications for SCINTIX® therapy
HAYWARD, Calif., July 23, 2025 — RefleXion Medical, an external‑beam theranostic oncology company, today announced that researchers and early adopters from leading academic centers will deliver 29 scientific presentations featuring SCINTIX® biology‑guided radiotherapy (BgRT) and the RefleXion® X1 platform at the 2025 American Association of Physicists in Medicine (AAPM) Annual Meeting, July 27–31 in Washington, D.C.
“These studies collectively advance the science that underpins SCINTIX therapy,” said Sean Shirvani, MD, MPH, chief medical officer at RefleXion. “From enabling precise multi‑target treatments, to sharing one‑year clinical outcomes in daily practice, to evaluating new radiotracers such as 68Ga‑PSMA, our collaborators are charting the path to bring biology‑guided radiotherapy to more patients with greater confidence and efficiency in the future.”
These studies collectively advance the science that underpins SCINTIX therapy
Sean Shirvani, MD, MPH,
Chief Medical Officer at RefleXion
The following presentations and programs highlight new research showcasing the potential of SCINTIX therapy and the X1 platform. Detailed information on all 29 presentations may be found here.
Featured Scientific Presentations at AAPM 2025:
Oral: Establishing Tumor Size-Dependent Contrast Requirements for Multi-Target Biology-Guided Radiation Therapy (BgRT), Muhammad Ramish Ashraf
Monday, July 28 at 7:50 AM in Room 202
Snap Orals: Impact of Positron Emission Tomography (PET) Image Characteristics on Biology-Guided Radiotherapy (BgRT) Treatment Accuracy, Andrew Groll, PhD
Wednesday, July 30 in Room 209 at 11:40AM
Snap Orals: Characterizing and Modeling Higher-Order Motions of the Collimator Subsystem on a 60RPM Gantry LINAC for Improved Small Target Dosimetry, Huixiao Chen, PhD
Wednesday, July 30 in Room 209 at 3:26PM
Posters: One-Year Experience of Biology-Guided Radiotherapy (BgRT) on PET-Linac in an Academic Center and Feasibility of Using 68Ga-PSMA for Biology-Guided Radiotherapy (BgRT) Treatment, Bin Cai, PhD
Sunday, July 27 at 3:30 PM in the Exhibit Hall Poster Lounge
Online Poster: A Simple and Reliable Method to Determine Patients Eligible for Treatment on the Novel Biology-Guided Radiotherapy (BgRT) System Based on FDG Uptake in Nearby Non-Treatment Regions, Roland Teboh
Available online
RefleXion is also hosting an industry lunch symposium during the AAPM annual meeting at 12:30 PM CDT on Monday, July 28. Physicists Chenyang Shen, Ph.D., Tyler Watkins, Ph.D., David Carlson, Ph.D., and Murat Surucu, Ph.D. will share their latest clinical experiences with SCINTIX biology-guided radiotherapy, highlight early clinical cases and share quality assurance procedures and practices.
About RefleXion Medical
RefleXion is a privately held theranostic oncology company located in Hayward, Calif., commercializing SCINTIX biology‑guided radiotherapy, a novel therapy that uses a single radiotracer injection to turn cancer cells into real‑time biological beacons to direct external‑beam radiotherapy. SCINTIX therapy is FDA‑cleared for FDG‑guided treatment of lung and bone tumors, including metastases, and is under investigation for additional tracers and indications. The RefleXion X1 platform is also cleared for conventional image‑guided radiotherapy for solid tumors anywhere in the body. For more information, visit www.reflexion.com.
Media Contact
contact@reflexion.com
+1 650.239.9080
